- MindMed is a biotech psychedelic medicine company focused on the clinical development of LSD, Ibogaine, MDMA, DMT, and psilocybin for anxiety, depression, addiction, ADHD, and more.
- Diverse and robust IP and drug development pipeline focusing on many underserved and large markets.
- Recently launched a new division focused on developing digital therapeutics for psychedelics.
- Filed to up-list to the NASDAQ following the successful IPO of another psychedelic company, Compass Pathways.
- Strong leadership team, partnerships with fantastic institutions, and backed by Kevin O'Leary (Shark Tank) and Bruce Linton (former CEO of Canopy Growth).
For further details see:
MindMed: Severely Undervalued With Massive Upside Yet To Come